This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Chinook Therapeutics Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Chinook Therapeutics.
Key information
22.6%
Earnings growth rate
28.0%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 63.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 10 Aug 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 80 | -247 | -286 | -253 | 8 |
| 12/31/2024 | 13 | -284 | -289 | -262 | 11 |
| 12/31/2023 | 3 | -253 | -290 | -243 | 5 |
| 6/30/2023 | 6 | -246 | -177 | -174 | N/A |
| 3/31/2023 | 5 | -216 | -146 | -143 | N/A |
| 12/31/2022 | 6 | -188 | -119 | -117 | N/A |
| 9/30/2022 | 57 | -118 | -105 | -103 | N/A |
| 6/30/2022 | 54 | -92 | -104 | -103 | N/A |
| 3/31/2022 | 54 | -97 | -101 | -99 | N/A |
| 12/31/2021 | 52 | -103 | -105 | -103 | N/A |
| 9/30/2021 | 1 | -160 | -124 | -122 | N/A |
| 6/30/2021 | 1 | -149 | -105 | -104 | N/A |
| 3/31/2021 | 1 | -114 | -82 | -80 | N/A |
| 12/31/2020 | 1 | -82 | -57 | -56 | N/A |
| 9/30/2020 | N/A | -52 | -19 | -19 | N/A |
| 6/30/2020 | N/A | -54 | -17 | -16 | N/A |
| 3/31/2020 | N/A | -48 | -16 | -15 | N/A |
| 12/31/2019 | N/A | -47 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 290A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 290A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 290A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 290A's revenue (63.8% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: 290A's revenue (63.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 290A's Return on Equity is forecast to be high in 3 years time